1. Results of the RENAISSANCE Study: REsponse to BNT162b2 COVID-19 vacciNe—short- And long-term Immune reSponSe evAluatioN in health Care workErs
- Author
-
Pani, A, Cento, V, Vismara, C, Campisi, D, Di Ruscio, F, Romandini, A, Senatore, M, Schenardi, P, Gagliardi, O, Giroldi, S, Zoppini, L, Moreno, M, Corradin, M, Epis, O, Ughi, N, Cuppari, I, Crocchiolo, R, Merli, M, Bosio, M, Rossini, S, Puoti, M, Scaglione, F, Pani A., Cento V., Vismara C., Campisi D., Di Ruscio F., Romandini A., Senatore M., Schenardi P. A., Gagliardi O. M., Giroldi S., Zoppini L., Moreno M., Corradin M., Epis O. M., Ughi N., Cuppari I., Crocchiolo R., Merli M., Bosio M., Rossini S., Puoti M., Scaglione F., Pani, A, Cento, V, Vismara, C, Campisi, D, Di Ruscio, F, Romandini, A, Senatore, M, Schenardi, P, Gagliardi, O, Giroldi, S, Zoppini, L, Moreno, M, Corradin, M, Epis, O, Ughi, N, Cuppari, I, Crocchiolo, R, Merli, M, Bosio, M, Rossini, S, Puoti, M, Scaglione, F, Pani A., Cento V., Vismara C., Campisi D., Di Ruscio F., Romandini A., Senatore M., Schenardi P. A., Gagliardi O. M., Giroldi S., Zoppini L., Moreno M., Corradin M., Epis O. M., Ughi N., Cuppari I., Crocchiolo R., Merli M., Bosio M., Rossini S., Puoti M., and Scaglione F.
- Abstract
Objective: To evaluate the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) anti-spike (S) IgG antibody production after vaccination with BNT162b2 and the protection from symptomatic breakthrough infections in health care workers. Methods: This prospective observational study (RENAISSANCE) had as a primary end point the evaluation of serologic response to BNT162b2 14 days after a second dose. SARS-CoV-2 anti-S IgG antibodies were evaluated with LIAISON SARS-CoV-2 TrimericS IgG assay (DiaSorin S.p.A.), which is able to detect the presence of both binding and neutralizing antibodies for trimeric spike glycoprotein. Participants were recruited from February 1, 2021, to February 22, 2021. Occurrence of vaccine breakthrough infections was assessed by reverse transcription–polymerase chain reaction on symptomatic and contact cases up to June 6, 2021. Results: Of 2569 staff evaluated, only 4 were nonresponders (0.16%; 95% CI, 0.04% to 0.41%). All 4 nonresponders were severely immunosuppressed and receiving treatment with mycophenolate mofetil or mycophenolic acid. At 14 days after the second dose, 67.5% (1733) of staff had anti-S IgG titers of 2000 BAU/mL or higher; 19.2% (494), between 1500 and 2000 BAU/mL; 9.8% (251), between 1000 and 1500 BAU/mL; and 3.4% (87), 1000 BAU/mL or lower. Women had a higher probability of having higher titers than men (64.5% [1044/1618] vs 58.3% [410/703]; P=.005). This was confirmed after adjustment for age group (odds ratio, 1.275; 95% CI, 1.062 to 1.531; P=.009). Four months after the end of the vaccination program, only 13 participants (0.26%) had experienced a breakthrough SARS-CoV-2 infection, including 1 nonresponder. This was the only participant requiring hospitalization for severe COVID-19. Conclusion: The vaccination campaign among health care workers at the ASST GOM Niguarda has resulted in a marked serologic response and reduction of incident COVID-19 cases. Yet, the lack of protection should not be overlooked in immu
- Published
- 2021